# AvMed

## **MEDICAL PRIOR AUTHORIZATION/STEP-EDIT REQUEST\***

**Directions:** The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; <u>fax to 1-877-535-1391</u>. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. If information provided is not complete, correct, or legible, authorization can be delayed.

**For Medicare Members:** Medicare Coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD) and Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. They can be found at: <u>https://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx</u>. Additional indications may be covered at the discretion of the health plan.

# **Drug Requested: Hemophilia Factors (Medical)**

Member Name:

## MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member AvMed #	#: Date of Birth:		
Prescriber Name:			
	ure: Date:		
<b>Office Contact Na</b>	nme:		
Phone Number:	Fax Number:		
NPI #:			
	<b>RMATION:</b> Authorization may be delayed if incomplete.		
Drug Name/Form	/Strength:		
Dosing Schedule:	Length of Therapy:		
Diagnosis:	ICD Code, if applicable:		
Weight (if applica	ble): Date weight obtained:		
	w. In checking this box, the timeframe does not jeopardize the life or health of the mem bility to regain maximum function and would not subject the member to severe pain.		
DRUG INFO	<b>DRMATON</b> : Listed below are the following HCPCS codes covered by AvMed.		
Check the appr	ropriate HCPCS code. If incomplete, authorization process may be delayed.		
HCPCS CODE	DESCRIPTION		
□ J7180	Corifact <sup>®</sup> (factor XIII antihemophilic factor concentrate, human)		
□ J7182	Novoeight <sup>®</sup> (factor VIII, antihemophilic factor, recombinant)		
□ J7183	Injection, Von Willebrand factor complex (Wilate <sup>®</sup> )		

**J7185** Injection, factor VIII (antihemophilic factor, recombinant) (Xyntha<sup>®</sup>)

(Continued on next page)

DRUG INFORMATON: Listed below are the following HCPCS codes covered by AvMed.				
<u>Check</u> the appropriate HCPCS code. If incomplete, authorization process may be delayed.				
HCPCS CODE	DESCRIPTION			
<b>J J</b> 7186	Injection, antihemophilic factor VIII/von Willebrand factor complex (human), per			
	factor VIII I.U. (Alphanate <sup>®</sup> )			
□ J7187				
□ J7188	Obizur (antihemophilic Factor VIII (Recombinant), Porcine Sequence)			
□ J7189	Factor VIIa (antihemophilic factor, recombinant) NovoSevent®RT			
□ J7190	Factor VIII (antihemophilic factor [human]) per IU: Alphanate <sup>®</sup> , Koate-DVI <sup>®</sup> , Monoclate-P <sup>®</sup> , Hemofil M <sup>®</sup>			
□ J7192	Factor VIII (antihemophilic factor, recombinant) per IU: Recombinate <sup>®</sup> , Kogenate FS <sup>®</sup> , Advate <sup>®</sup>			
□ J7193	Factor IX (antihemophilic factor, purified, non-recombinant) per IU, AlphaNine SD®			
□ J7194	Factor IX, complex, per IU: Proplex T <sup>®</sup> , Bebulin VH <sup>®</sup> , Profilnine SD <sup>®</sup>			
□ J7195	Factor IX (antihemophilic factor, recombinant) per IU: BeneFIX <sup>®</sup> , Ixinity <sup>®</sup>			
□ J7198	□ J7198 Feiba <sup>®</sup> NF (anti-inhibitor coagulant complex)			
□ J7199	Altuviiio <sup>™</sup> (antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl)			
□ J7200	□ J7200 Rixubis <sup>®</sup> (factor IX, antihemophilic factor, recombinant)			
□ J7201	Alprolix <sup>®</sup> (factor IX, Fc fusion protein, recombinant)			
□ J7202	Idelvion <sup>®</sup> (factor IX, albumin fusion protein, recombinant)			
□ J7203	Rebinyn <sup>®</sup> (factor IX, glycopegylated antihemophilic factor, recombinant)			
□ J7204	Espercot <sup>®</sup> (factor VIII, glycopegylated-exei antihemophilic factor, recombinant)			
□ J7205	Eloctate <sup>®</sup> (factor VIII, Fc fusion protein, recombinant)			
□ J7207	Adynovate® (factor VIII, pegylated antihemophilic factor, recombinant)			
□ J7208	□ J7208 Jivi <sup>®</sup> (factor VIII, pegylated-aucl antihemophilic factor, recombinant)			
□ J7209	Nuwiq <sup>®</sup> (factor VIII, antihemophilic factor, recombinant)			
<b>J7210</b>	Afstyla® (factor VIII, antihemophilic factor, recombinant)			
□ J7211	Kovaltry® (factor VIII, antihemophilic factor, recombinant)			
□ J7212	Sevenfact <sup>®</sup> (factor VIIa, antihemophilic factor, recombinant)			

**CLINICAL CRITERIA**: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

Hemophilia A – Factor VIII Disease	ICD Code:
Hemophilia B – Factor IX Disease	ICD Code:
von Willebrand Disease	ICD Code:

### Medication being provided by: Please check applicable box below.

- □ Location/site of drug administration: \_\_\_\_
  - NPI or DEA # of administering location: \_\_\_\_\_

#### <u>OR</u>

**D** Specialty Pharmacy – Proprium Rx

For urgent reviews: Practitioner should call AvMed Pre-Authorization Department if they believe a standard review would subject the member to adverse health consequences. AvMed's definition of urgent is a lack of treatment that could seriously jeopardize the life or health of the member or the member's ability to regain maximum function.

\*\*Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.\*\* \*<u>Previous therapies will be verified through pharmacy p</u>

aid claims or submitted chart notes.\*